Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 10/20 | 0.36 |
| ▸ | FEN1 | P39748 | 10/20 | 0.36 |
| ▸ | DDR1 | Q08345 | 6/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29308350 | 0.90 | FLT3 (0.40) | ALOX5APFEN1DDR1SCN9A | |
| SCHEMBL18751256 | 0.87 | TP53 (0.44) | ALOX5APFEN1DDR1TP53POLB | |
| SCHEMBL19219734 | 0.85 | TP53 (0.47) | ALOX5APFEN1DDR1TP53POLB | |
| SCHEMBL18751266 | 0.82 | ALOX5AP (0.41) | ALOX5APFEN1TP53POLBGAA | |
| SCHEMBL30843066 | 0.78 | DDR1 (0.39) | ALOX5APFEN1DDR1SCN9A | |
| SCHEMBL19017140 | 0.78 | DDR1 (0.39) | ALOX5APFEN1DDR1PTGDR2 | |
| SCHEMBL19017507 | 0.78 | DDR1 (0.41) | ALOX5APFEN1DDR1PTGDR2 | |
| SCHEMBL29755613 | 0.77 | ALOX5AP (0.39) | ALOX5APFEN1DDR1PTGDR2 | |
| SCHEMBL18988945 | 0.77 | ALOX5AP (0.39) | ALOX5APFEN1DDR1PTGDR2 | |
| SCHEMBL18989081 | 0.76 | ALOX5AP (0.39) | ALOX5APFEN1DDR1PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037326-B2 | Diaryl-azole compound and formulation for controlling harmful organism | NIPPON SODA CO., LTD. (JP) | 2024-07-16 | — | — | US | disclosed |
| US-20220033384-A1 | DIARYL-AZOLE COMPOUND AND FORMULATION FOR CONTROLLING HARMFUL ORGANISM | NIPPON SODA CO., LTD. (JP) | 2022-02-03 | — | — | US | disclosed |
| US-11180485-B2 | Diaryl-azole compound and formulation for controlling harmful organism | NIPPON SODA CO., LTD. (JP) | 2021-11-23 | — | — | US | disclosed |
| EP-3514146-A1 | DIARYL AZOLE COMPOUND AND PESTICIDE | Nippon Soda Co., Ltd. (JP) | 2019-07-24 | — | — | EP | disclosed |
| US-20190185459-A1 | DIARYL-AZOLE COMPOUND AND FORMULATION FOR CONTROLLING HARMFUL ORGANISM | NIPPON SODA CO., LTD. (JP) | 2019-06-20 | — | — | US | disclosed |
| WO-2018052035-A1 | DIARYL AZOLE COMPOUND AND PESTICIDE | 日本曹達株式会社 | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033384-A1 | DIARYL-AZOLE COMPOUND AND FORMULATION FOR CONTROLLING HARMFUL ORGANISM | CRY1, CRKL, CDC5L | ALOX5AP 4111/4885FEN1 4477/4885DDR1 1096/4885 |
| US-20190185459-A1 | DIARYL-AZOLE COMPOUND AND FORMULATION FOR CONTROLLING HARMFUL ORGANISM | CRY1, CRKL, CDC5L | ALOX5AP 4111/4885FEN1 4477/4885DDR1 1096/4885 |
| US-12037326-B2 | Diaryl-azole compound and formulation for controlling harmful organism | CRY1, CRKL, CDC5L | ALOX5AP 4111/4885FEN1 4477/4885DDR1 1096/4885 |
| US-11180485-B2 | Diaryl-azole compound and formulation for controlling harmful organism | CRY1, CRKL, CDC5L | ALOX5AP 4111/4885FEN1 4477/4885DDR1 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.